Massachusetts Financial Services
BIO icon

Massachusetts Financial Services’s Bio-Rad Laboratories Class A BIO Stock Holding History

Massachusetts Financial Services’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Sell
7,850
-388,300
-98% -$110M ﹤0.01% 826
2026
Q1 		$110M Sell
396,150
-3,057
-0.8% -$880K 0.04% 345
2025
Q4 		$121M Buy
399,207
+390,593
+4,534% +$122M 0.04% 352
2025
Q3 		$2.42M Buy
8,614
+4,888
+131% +$1.33M ﹤0.01% 751
2025
Q2 		$899K Sell
3,726
-536
-13% -$127K ﹤0.01% 821
2025
Q1 		$1.04M Buy
4,262
+665
+18% +$200K ﹤0.01% 807
2024
Q4 		$1.18M Sell
3,597
-50,566
-93% -$17.2M ﹤0.01% 805
2024
Q3 		$18.1M Sell
54,163
-294,377
-84% -$93.5M 0.01% 605
2024
Q2 		$95.2M Buy
348,540
+1,288
+0.4% +$375K 0.03% 381
2024
Q1 		$120M Buy
347,252
+24,958
+8% +$8.21M 0.04% 353
2023
Q4 		$104M Sell
322,294
-1,423
-0.4% -$446K 0.03% 374
2023
Q3 		$116M Buy
+323,717
New +$125M 0.04% 339

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Massachusetts Financial Services's BIO Position: Q2 2026 in Review

Massachusetts Financial Services reduced its Bio-Rad Laboratories Class A (BIO) stake by 98% in Q2 2026, selling an estimated $110M and leaving 7,850 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #826.

Massachusetts Financial Services first reported a position in BIO in Q3 2023 and has held it in 12 quarters since. The position peaked at $121M in Q4 2025. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Massachusetts Financial Services held 7,850 shares of Bio-Rad Laboratories Class A worth $2.3M as of Q2 2026.
  • Massachusetts Financial Services sold 388,300 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $110M.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Massachusetts Financial Services's portfolio in Q2 2026, its #826 holding.
  • Massachusetts Financial Services first reported a position in Bio-Rad Laboratories Class A in Q3 2023 and has held it in 12 quarters since.
  • Massachusetts Financial Services's Bio-Rad Laboratories Class A position peaked at $121M in Q4 2025.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.